Maltol |
Catalog No.GC36536
One-Click Copy Product Info
|
Maltol is a naturally occurring organic compound that is flavour enhancer and flavouring agent.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 118-71-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Maltol is a naturally occurring organic compound that is flavour enhancer and flavouring agent[1]. Maltol is also an antioxidant agent and a metal ion chelator[2][3]. Maltol is usually be used in the field of catalysis, food chemistry, and medicine[4][5].
In vitro, treatment of B16F10 cells with Maltol (5 or 10μg/ml in medium; 72h) reduced melanin contents, tyrosinase activity, and expression levels of tyrosinase and tyrosinase-related protein 1, suppressed the proliferative capacity, induced cell cycle arrest, increased apoptotic rates by elevating cleaved caspase-3 and PARP, and demonstrated a synergistic effect with cisplatin in inhibiting growth and promoting apoptosis[6].
In vivo, Oral treatment of D-galactose-induced liver and kidney aging and injury mice with Maltol (50 or 100mg/kg/day; 4 weeks） activated aging-associated proteins including p53, p21, and p16 followed by inhibiting malondialdehyde (MDA)'s over-production and increasing the levels of antioxidant enzymes[7]. Oral gavage of Maltol (15 or 30mg/kg; twice a week) for 12 weeks in intervertebral disc degeneration (IDD) mice inhibited the degradation of ECM and inflammatory response by suppressing the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome-mediated pyroptosis, increased anabolic protein expression, decreased catabolic protein expression, and reduced the secretion of inflammatory mediators such as IL-18 and IL-1β[8].
References:
[1] Han, Y., Xu, Q., Hu, J. N., Han, X. Y., Li, W., & Zhao, L. C. (2015). Maltol, a food flavoring agent, attenuates acute alcohol-induced oxidative damage in mice. Nutrients, 7(1), 682–696.
[2] Guo, N., , Li, C., , Liu, Q., , Liu, S., , Huan, Y., , Wang, X., , Bai, G., , Yang, M., , Sun, S., , Xu, C., , & Shen, Z., (2018). Maltol, a food flavor enhancer, attenuates diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. Food & function, 9(12), 6287–6297.
[3] Yang, Y., Wang, J., Xu, C., Pan, H., & Zhang, Z. (2006). Maltol inhibits apoptosis of human neuroblastoma cells induced by hydrogen peroxide. Journal of biochemistry and molecular biology, 39(2), 145–149.
[4] Krishnakumar, V., Barathi, D., Mathammal, R., Balamani, J., & Jayamani, N. (2014). Spectroscopic properties, NLO, HOMO-LUMO and NBO of maltol. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 121, 245–253.
[5] Thompson, K. H., Barta, C. A., & Orvig, C. (2006). Metal complexes of maltol and close analogues in medicinal inorganic chemistry. Chemical Society reviews, 35(6), 545–556.
[6] Han, N. R., Park, H. J., Ko, S. G., & Moon, P. D. (2023). Maltol has anti-cancer effects via modulating PD-L1 signaling pathway in B16F10 cells. Frontiers in pharmacology, 14, 1255586.
[7] Sha, J. Y., Li, J. H., Zhou, Y. D., Yang, J. Y., Liu, W., Jiang, S., Wang, Y. P., Zhang, R., Di, P., & Li, W. (2021). The p53/p21/p16 and PI3K/Akt signaling pathways are involved in the ameliorative effects of maltol on D-galactose-induced liver and kidney aging and injury. Phytotherapy research : PTR, 35(8), 4411–4424.
[8] Gong, Y., Qiu, J., Jiang, T., Li, Z., Zhang, W., Zheng, X., He, Z., Chen, W., Wang, Z., Feng, X., Wang, M., & Hong, Z. (2023). Maltol ameliorates intervertebral disc degeneration through inhibiting PI3K/AKT/NF-κB pathway and regulating NLRP3 inflammasome-mediated pyroptosis. Inflammopharmacology, 31(1), 369–384.
| Cell experiment [1]: | |
Cell lines | B16F10 cells |
Preparation Method | B16F10 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. B16F10 cells (1 × 105/well) were exposed to Maltol(5 or 10μg/ml in medium) and then treated with α-MSH (100nM) for 72h. For the melanin content assay, the cell pellets were dissolved in 1N NaOH containing 10% dimethyl sulfoxide (DMSO) and subjected to cell lysis for 1h at 80°C. The optical density of melanin content was spectrophotometrically measured with a microplate reader (405nm). In the tyrosinase activity assay, the cell pellets were lysed in PBS containing 1% Triton X-100 for 2h at 80°C. A freshly prepared substrate (L-DOPA, 10mM) was then added and incubated for 30min at 37°C. The resulting absorbance was spectrophotometrically analyzed with a microplate reader (475nm). |
Reaction Conditions | 5 or 10μg/ml; 72h |
Applications | Maltol reduced melanin contents and tyrosinase activity. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | C57BL/6 mice were randomly assigned to four groups (control group, spinal instability group, spinal instability+15mg/kg Maltol group, and spinal instability+30mg/kg Maltol group). The mice in the spinal instability group and Maltol groups were subjected to surgical manipulation to generate the lumbar spine instability model. Following surgery, the corresponding drug treatment was administered according to the grouping. Mice in the control group were treated with phosphate-buffered saline (PBS), while those in the Maltol groups received 15mg/kg or 30mg/kg Maltol (dissolved in PBS) by gavage twice a week, respectively, and the IDD group was not treated with the drug. Subsequently, mice were euthanized 12 weeks after surgery with excessive 1% pentobarbital, and IVD tissues were taken for histological and immunohistochemical analysis. |
Dosage form | 15 or 30mg/kg; p.o.; twice a week for 12 weeks |
Applications | Maltol inhibited the degradation of ECM and inflammatory response, increased anabolic protein expression, decreased catabolic protein expression, and reduced the secretion of inflammatory mediators such as IL-18 and IL-1β. |
References: | |
| Cas No. | 118-71-8 | SDF | |
| Canonical SMILES | O=C1C(O)=C(C)OC=C1 | ||
| Formula | C6H6O3 | M.Wt | 126.11 |
| Solubility | DMSO: 100 mg/mL (792.96 mM); Water: 7.69 mg/mL (60.98 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 7.9296 mL | 39.6479 mL | 79.2959 mL |
| 5 mM | 1.5859 mL | 7.9296 mL | 15.8592 mL |
| 10 mM | 793 μL | 3.9648 mL | 7.9296 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)